Cargando…

Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries

Limited data about the long-term prognosis and response to therapy in pulmonary arterial hypertension patients with World Health Organization functional class I/II symptoms are available. PubMed and Embase were searched for publications of observational registries and randomized, controlled trials i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Nick H., Fisher, Micah, Poch, David, Zhao, Carol, Shah, Mehul, Bartolome, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691927/
https://www.ncbi.nlm.nih.gov/pubmed/33282180
http://dx.doi.org/10.1177/2045894020935291
_version_ 1783614399097864192
author Kim, Nick H.
Fisher, Micah
Poch, David
Zhao, Carol
Shah, Mehul
Bartolome, Sonja
author_facet Kim, Nick H.
Fisher, Micah
Poch, David
Zhao, Carol
Shah, Mehul
Bartolome, Sonja
author_sort Kim, Nick H.
collection PubMed
description Limited data about the long-term prognosis and response to therapy in pulmonary arterial hypertension patients with World Health Organization functional class I/II symptoms are available. PubMed and Embase were searched for publications of observational registries and randomized, controlled trials in pulmonary arterial hypertension patients published between January 2001 and January 2018. Eligible registries enrolled pulmonary arterial hypertension patients ≥18 years, N > 30, and reported survival by functional class. Randomized, controlled trial inclusion criteria were pulmonary arterial hypertension patients ≥18 years, ≥6 months of treatment, and morbidity, mortality, or time to worsening as end points reported by functional class. The primary outcomes were survival for registries and clinical event rates for randomized, controlled trials. Separate random effects models were calculated for registries and randomized, controlled trials. Four randomized, controlled trials (n = 2482) and 10 registries (n = 6580) were included. Registries enrolled 9%–47% functional class I/II patients (the vast majority being functional class II) with various pulmonary arterial hypertension etiologies. Survival rates for functional class I/II patients at one, two, and three years were 93% (95% confidence interval (CI): 91%–95%), 86% (95% CI: 82%–89%), and 78% (95% CI: 73%–83%), respectively. The hazard ratio for the treatment effect in randomized, controlled trials overall was 0.61 (95% CI: 0.51–0.74) and 0.60 (95% CI: 0.44–0.82) for functional class I/II patients and 0.62 (95% CI: 0.49–0.78) for functional class III/IV. The calculated risk of death of 22% within three years for functional class I/II patients underlines the need for careful assessment and optimal treatment of patients with functional class I/II disease. The randomized, controlled trial analysis demonstrates that current medical therapies have a beneficial treatment effect in this population.
format Online
Article
Text
id pubmed-7691927
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-76919272020-12-04 Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries Kim, Nick H. Fisher, Micah Poch, David Zhao, Carol Shah, Mehul Bartolome, Sonja Pulm Circ Original Research Article Limited data about the long-term prognosis and response to therapy in pulmonary arterial hypertension patients with World Health Organization functional class I/II symptoms are available. PubMed and Embase were searched for publications of observational registries and randomized, controlled trials in pulmonary arterial hypertension patients published between January 2001 and January 2018. Eligible registries enrolled pulmonary arterial hypertension patients ≥18 years, N > 30, and reported survival by functional class. Randomized, controlled trial inclusion criteria were pulmonary arterial hypertension patients ≥18 years, ≥6 months of treatment, and morbidity, mortality, or time to worsening as end points reported by functional class. The primary outcomes were survival for registries and clinical event rates for randomized, controlled trials. Separate random effects models were calculated for registries and randomized, controlled trials. Four randomized, controlled trials (n = 2482) and 10 registries (n = 6580) were included. Registries enrolled 9%–47% functional class I/II patients (the vast majority being functional class II) with various pulmonary arterial hypertension etiologies. Survival rates for functional class I/II patients at one, two, and three years were 93% (95% confidence interval (CI): 91%–95%), 86% (95% CI: 82%–89%), and 78% (95% CI: 73%–83%), respectively. The hazard ratio for the treatment effect in randomized, controlled trials overall was 0.61 (95% CI: 0.51–0.74) and 0.60 (95% CI: 0.44–0.82) for functional class I/II patients and 0.62 (95% CI: 0.49–0.78) for functional class III/IV. The calculated risk of death of 22% within three years for functional class I/II patients underlines the need for careful assessment and optimal treatment of patients with functional class I/II disease. The randomized, controlled trial analysis demonstrates that current medical therapies have a beneficial treatment effect in this population. SAGE Publications 2020-11-25 /pmc/articles/PMC7691927/ /pubmed/33282180 http://dx.doi.org/10.1177/2045894020935291 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Kim, Nick H.
Fisher, Micah
Poch, David
Zhao, Carol
Shah, Mehul
Bartolome, Sonja
Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries
title Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries
title_full Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries
title_fullStr Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries
title_full_unstemmed Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries
title_short Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries
title_sort long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691927/
https://www.ncbi.nlm.nih.gov/pubmed/33282180
http://dx.doi.org/10.1177/2045894020935291
work_keys_str_mv AT kimnickh longtermoutcomesinpulmonaryarterialhypertensionbyfunctionalclassametaanalysisofrandomizedcontrolledtrialsandobservationalregistries
AT fishermicah longtermoutcomesinpulmonaryarterialhypertensionbyfunctionalclassametaanalysisofrandomizedcontrolledtrialsandobservationalregistries
AT pochdavid longtermoutcomesinpulmonaryarterialhypertensionbyfunctionalclassametaanalysisofrandomizedcontrolledtrialsandobservationalregistries
AT zhaocarol longtermoutcomesinpulmonaryarterialhypertensionbyfunctionalclassametaanalysisofrandomizedcontrolledtrialsandobservationalregistries
AT shahmehul longtermoutcomesinpulmonaryarterialhypertensionbyfunctionalclassametaanalysisofrandomizedcontrolledtrialsandobservationalregistries
AT bartolomesonja longtermoutcomesinpulmonaryarterialhypertensionbyfunctionalclassametaanalysisofrandomizedcontrolledtrialsandobservationalregistries